|
| |
Dilated cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM)
Peripartum cardiomyopathy
Dilated
cardiomyopathy
Pathophysiology
- impaired LV and/or RV systolic pump function leading to cardiac enlargement
- mural thrombi often present, particularly in LV apex
Pathology
- extensive area of interstitial and perivascular fibrois with minimal
necrosis and cellular infiltration
Aetiology
probably end result of myocardial damage due to a variety of toxic,
metabolic or infective agents. None of these causes apparent in many patients
in some patients may be the late sequel of acute viral myocarditis
minority of patients have familial forms
Clinical features
features of LVF and RVF
arrhythmias
some patients have LV dilatation for months or even years before becoming
symptomatic
vague chest pain may be present
typical angina unusual and presence suggests concomitant IHD
3rd and 4th heart sounds common
± MR or TR
diastolic murmurs, valvular calcification and severe hypertension reduce
likelihood of cardiomyopathy
systemic embolization common even in patients in sinus rhythm
Investigation
CXR
LV enlargement
generalized cardiomegaly often seen. Sometimes due to concomitant
pericardial effusion
± pulmonary venous hypertension, interstitial or alveolar oedema
ECG
sinus tachycardia or AF
ventricular arrhythmias
LA enlargement
diffuse non-specific ST-T wave abnormalities
± intraventricular conduction defects
Echo and radionuclide ventriculography
LV enlargement
normal or minimally thickened or thinned LV walls
pericardial effusion common
Gallium scan
may identify patients with dilated cardiomyopathy and concomitant
myocarditis
Haemodynamic studies
cardiac output does not increase normally with exercise
LVEDP, LAP, PCWP elevated
RVEDP and CVP also elevated when RVF develops
angiography: dilated diffusely hypokinetic LV, often with some MR. Normal
coronaries
Endomyocardial biopsy
may be helpful in excluding conditions such as myocardial amyloid
Management
Drugs
standard management of cardiac failure. ACE inhibitors improve survival
anticoagulation in absence of contraindication
avoid strenuous exercise
some suggestion that cautious introduction of beta blockers may improve
symptoms
avoid anti-arrhythmics if possible because of pro-arrhythmic effects unless
needed to treat symptomatic or serious arrhythmias
Pacing
patients who do not respond to medical therapy may benefit from dual chamber
pacing with short AV interval with improvement in haemodynamics and symptoms
benefits occur primarily in patients with prolonged PR interval
results in reduced MR, increased LV filling and decreased ventricular wall
stress
should be considered as investigational at present
Cardiac transplantation
consider for patients with advanced disease who are refractory to medical
therapy and have no contraindications. (More
on cardiac transplantation.)
Prognosis
Most patients deteriorate inexorably and the majority, particularly those
> 55 years, die within 2 years of onset of symptoms. Death usually due to CCF
or VT or
bradyarrhythmia. Sudden death is a constant threat.
Hypertrophic
cardiomyopathy
Pathophysiology
hypertrophied muscle leads to diastolic dysfunction due to decreased
ventricular compliance. Results primarily from an abnormality in calcium
handling with attendant intracellular calcium overload
heterogenous LVH, often with asymmetric septal hypertrophy: upper portion of
septum is preferentially hypertrophied compared with posterobasal LV free wall
dynamic LV outflow pressure gradient. Related to narrowing of subaortic area
as a result of midsystolic apposition of anterior mitral valve leaflet against
the hypertrophied septum (ie systolic anterior motion of mitral valve. Only
1/4 of patients have an outflow tract gradient
three basic mechanisms are involved in production of dynamic pressure
gradient: increased LV contractility (reduces LV systolic volume and
increases ejection velocity of blood moving through the outflow tract, thus
drawing the anterior leaflet against the septum as a result of reduced
distending pressure), decreased preload (reduces further the size of
the outflow tract) and decreased aortic impedance and pressure
(increases velocity of flow through the subaortic area and also reduces LV
systolic volume
Management
Calcium antagonists
verapamil and diltiazem may reduce stiffness of ventricle, reduce elevated
diastolic pressures, increase exercise tolerance and, in some cases, reduce
the severity of outflow tract gradient
Disopyramide
has been used in some patients to decrease contractility and outflow
gradient
Pacing
may be useful for patients refractory to medical therapy
early results suggest that both symptoms and haemodynamic function can be
improved if dual chamber pacing with short AV interval is used
benefits thought to be due to reduced gradient across LV outflow tract. This
is caused by pacing from the RV apex which creates a functional LBBB and
paradoxical motion of interventricular septum
Surgery
myotomy or myectomy of hypertrophied septum may result in lasting
symptomatic improvement in about 3/4 of operated patients
mortality approx. 5%: limits operationto severely symptomatic patients with
large pressure gradients who are unresponsive to medical management
Miscellaneous
avoid drugs which increase contractility, or decrease afterload or preload
endocarditis prophylaxis particularly in patients with resting obstruction
and MR
avoid strenous exercise in all patients regardless of symptoms: sudden death
often occurs during or just after physical exertion
Prognosis
natural history variable
many patients demonstrate improvement or stabilization of symptoms with time
AF common late in course of disease: onset may lead to an increase in
symptoms
major cause of mortality is sudden death. Predictors include age < 30
years, VT on Holter, marked ventricular hypertrophy, syncope and family
history of sudden death
no correlation between risk of sudden death and severity of symptoms or
presence or severity of outflow gradient. Haemodynamic factors appear to play
a role. Likely that most deaths are due to ventricular arrhythmias
Further reading
Kusumoto FM, Goldschlager N. Cardiac pacing. NEJM, 1996; 334:89-98
Peripartum
cardiomyopathy
Definition
Primary cardiac failure of uncertain cause during last month of pregnancy or
first 6 months postpartum.
Epidemiology
- rare
- higher incidence in older, multiparous women
- associated with pre-eclampsia, obesity, breast-feeding, multiple gestations
Clinical features
- presents with progressive signs and symptoms of CCF
Investigations
- cardiomegaly, pulmonary venous congestion and pulmonary oedema on CXR
- Echo: atrial and ventricular enlargement and decreased ventricular function
- endomyocardial biopsy: degenerative changes including hypertrophy, fibrosis,
lipid deposition
Management
- conventional management of cardiac failure +/- shock
- ensure uterine displacement
- early delivery removes some cardiovascular stress from mother
- anti-coagulate after delivery: high incidence of embolic events
© Charles Gomersall July 1999
|